Savient Pharmaceuticals, Inc. Finalizes Agreement For Settlement Of Mircette(R) Litigation; Transaction Terminates And Results In $13.75 Million Payment To Savient

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Dec. 2, 2005--Savient Pharmaceuticals, Inc. ("Savient") (NASDAQ: SVNTE), an emerging specialty pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that address unmet medical needs in niche and broader markets, announced today that it has concluded with Barr Pharmaceuticals, Inc. ("Barr") (NYSE: BRL), Organon USA Inc. and Organon (Ireland) Ltd. ("Organon"), business units of Akzo Nobel NV (Nasdaq: AKZOY), an agreement for the settlement of the ongoing patent litigation regarding Barr's generic version of Mircette(R), which Barr markets under the trade name Kariva(R). Under the terms of the transaction Barr will acquire the exclusive rights to Organon's Mircette (Desogestrel/Ethinyl Estradiol) oral contraceptive product.